According to the findings of the ARASENS trial (NCT02799602), presented by Bayer at the 2022 ASCO GU, Nubeqa resulted in a 32.5% reduction in the risk of death, with a median follow-up of 43.7 months for darolutamide. Nubeqa provided a consistent overall survival advantage across predefined subgroups. The median OS in the darolutamide arm was not estimable compared to 48.9 months in the placebo arm. At 48 months, the rates of OS were 62.7% for Nubeqa. The safety profile of the two arms was comparable. In conclusion, findings from the phase III ARASENS study indicated that early treatment with Nubeqa with ADT plus docetaxel increased overall survival much more th...
